Nebulised liposomal-amphotericin-B as maintenance therapy in ABPA: a randomised, multicentre, trial.
Cendrine GodetFrancis CouturaudSylvain Marchand-AdamChristophe PisonGagnadoux FredericElodie BlanchardCamille TailléBruno PhilippeSandrine HirschiClaire AndréjakArnaud BourdinCécile ChenivesseStéphane DominiqueLaurence BassinetMarlène Murris-EspinFrédéric RivièreGilles GarciaDenis CaillaudFrançois-Xavier BlancFrançois GoupilAnne BergeronAnne GondouinJean-Pierre FratThomas FlamentBoubou CamaraPascaline PriouAnne-Laure BrunFrançois LaurentStéphanie RagotJacques Cadranelnull nullPublished in: The European respiratory journal (2021)
In ABPA, maintenance therapy using nebulised liposomal-amphotericin-B did not reduce the risk of severe clinical exacerbation. The presence of some positive secondary outcomes creates clinical equipoise for further research.